Literature DB >> 17845857

Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2).

Julie A Bergeon1, Istvan Toth.   

Abstract

The dipeptide l-Glu-l-Trp-OH (IM862) is currently under development for the treatment of certain cancers and immuno-deficiency disorders. However, due to its highly hydrophilic character, IM862 demonstrates low permeability across biological membranes, including the gastro-intestinal track, which makes it not orally available. In this study, the effect of lipid conjugation on the stability and intestinal permeability of the IM862 amide derivative l-Glu-l-Trp-NH(2) was investigated using enzymatic extracts and monolayers of Caco-2 cells, respectively. A series of eleven novel lipopeptide analogues of l-Glu-l-Trp-NH(2) was synthesized using tert-butyloxycarbonyl or 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis. In vitro assays demonstrated an improved stability to proteolytic enzymes and increased intestinal permeability for several conjugates, thereby supporting the hypothesis that lipidation may provide a means to enable the oral administration of IM862.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845857     DOI: 10.1016/j.bmc.2007.07.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia.

Authors:  Ying-Shan Chen; Colin R Green; Rebecca Teague; Joshua Perrett; Helen V Danesh-Meyer; Istvan Toth; Ilva D Rupenthal
Journal:  Drug Deliv Transl Res       Date:  2015-10       Impact factor: 4.617

2.  Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP-1.

Authors:  Yvonne M te Welscher; Daniel J-F Chinnapen; Lydia Kaoutzani; Randall J Mrsny; Wayne I Lencer
Journal:  J Control Release       Date:  2013-12-23       Impact factor: 9.776

3.  Therapeutic approaches using host defence peptides to tackle herpes virus infections.

Authors:  Håvard Jenssen
Journal:  Viruses       Date:  2009-11-18       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.